Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1140680 (
ovarian cancer
)
28,141
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
K1 is a monoclonal antibody that reacts with a cell surface antigen (CAK1) found in human mesothelia and nonmucinous ovarian tumors. In this article, the characteristics of the
CAK1 antigen
have been examined in detail. Using immunofluorescence microscopy, we have found that the CAK1 signal is removed from the cell surface by treatment with proteases or by phosphatidylinositol-phospholipase C, but not by neuraminidase and beta-galactosidase. The phosphatidylinositol-phospholipase C-released material was found to contain the
CAK1 antigen
which was detected by a competition radioimmunoassay. The phosphatidylinositol-phospholipase C-released
CAK1 antigen
was examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting and found to be approximately 40 kDa protein. The CAK1-K1 antibody complex remains on the cell surface and is poorly internalized, as shown by an acid wash immunofluorescence internalization assay. An immunotoxin composed of K1 and Lys-PE40, a mutant form of Pseudomonas exotoxin lacking the cell binding domain, was not cytotoxic, supporting the conclusion that the CAK1-K1 antibody complex is not internalized. However, an immunotoxin composed of K1 and native Pseudomonas exotoxin was selectively cytotoxic to cells expressing the
CAK1 antigen
. This cytotoxicity is due to the fact that domain I of Pseudomonas exotoxin promotes internalization of antigens which are not internalized or bound to antibody alone. Our results suggest that CAK1 is a polypeptide that is expressed on mesothelial cells and many ovarian cancers, and that K1 may be useful as a targeting agent for the immunotherapy of human
ovarian cancer
.
...
PMID:Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. 172 78
Mesothelin
is a glycosylphosphatidylinositol-linked glycoprotein highly expressed in mesothelial cells, mesotheliomas, and
ovarian cancer
, but the biological function(s) of the protein is not known. We have analyzed the expression of the mouse
mesothelin
gene in different developmental stages and in various adult tissues by Northern hybridization. The 2.5-kb
mesothelin
transcript was detected in the mRNA of E 7.0, E 15.0, and E 17.0 stages of mouse development. In adult tissues the
mesothelin
gene was expressed in lung, heart, spleen, liver, kidney, and testis. To directly assess the function of the
mesothelin
in vivo, we generated mutant mice in which the
mesothelin
gene was inactivated by replacing it with the neomycin resistance gene. In homozygous mutant mice neither
mesothelin
mRNA nor the protein product was detected. Null mutant mice were obtained in accordance with Mendelian laws, and both males and females produced offspring normally. No anatomical or histological abnormalities were detected in any tissues where
mesothelin
was reportedly expressed in wild-type mice. Our results demonstrate that
mesothelin
function is not essential for growth or reproduction in mice.
...
PMID:Mesothelin is not required for normal mouse development or reproduction. 1073 93
Mesothelin
, a differentiation antigen, is a 40-kD glycosylphosphatidylinositol-linked cell-surface glycoprotein, that is present on the surface of normal mesothelium and is overexpressed in many patients with epithelial ovarian cancer and malignant mesotheliomas. Monoclonal antibody K1 is a murine immunoglobulin G1 that recognizes
mesothelin
. LysPE38QQR is a truncated form of Pseudomonas exotoxin that lacks the cell-binding domain, but retains the translocation and adenosine diphosphate-ribosylation domains. It has a single lysine residue near the amino terminus that is available for conjugation to antibodies. To prevent chemical conjugation of the antibody to lysine residues at the C-terminus of Pseudomonas exotoxin, the two lysine residues at positions 590 and 606 were mutated to glutamine, and the lysine residue at position 613 was mutated to arginine. Monoclonal antibody K1 was chemically conjugated with LysPE38QQR, by modifying the antibody with sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate and coupling it with SPDP N-succinimidyl 3-(2-pyridyldithio)propionate-modified LysPE38QQR. The resulting immunotoxin K1-LysPE38QQR was highly toxic to A431-K5 cells (a human epidermoid carcinoma cell line transfected with a
mesothelin
expression plasmid) with a half-maximal inhibitory concentration of 3-6 ng/mL. The immunotoxin had negligible activity against A431 cells, which do not express
mesothelin
(median inhibitory concentration > 100 ng/mL). This immunotoxin also caused complete regression of tumors in nude mice that received xenografts of
mesothelin
-positive human carcinomas. These results show that immunotoxins directed against
mesothelin
are a therapeutic option that merits further investigation for the treatment of
ovarian cancer
and malignant mesotheliomas.
...
PMID:Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. 1091 57
Difficulties in the detection, diagnosis, and treatment of
ovarian cancer
result in an overall low survival rate of women with this disease. A better understanding of the pathways involved in ovarian tumorigenesis will likely provide new targets for early and effective intervention. Here, we have used serial analysis of gene expression (SAGE) to generate global gene expression profiles from various ovarian cell lines and tissues, including primary cancers, ovarian surface epithelia cells, and cystadenoma cells. The profiles were used to compare overall patterns of gene expression and to identify differentially expressed genes. We have sequenced a total of 385,000 tags, yielding >56,000 genes expressed in 10 different libraries derived from ovarian tissues. In general,
ovarian cancer
cell lines showed relatively high levels of similarity to libraries from other cancer cell lines, regardless of the tissue of origin (ovarian or colon), indicating that these lines had lost many of their tissue-specific expression patterns. In contrast, immortalized ovarian surface epithelia and ovarian cystadenoma cells showed much higher similarity to primary ovarian carcinomas than to primary colon carcinomas. Primary tissue specimens therefore appeared to be a better model for gene expression analyses. Using the expression profiles described above and stringent selection criteria, we have identified a number of genes highly differentially expressed between nontransformed ovarian epithelia and ovarian carcinomas. Some of the genes identified are already known to be overexpressed in
ovarian cancer
, but several represent novel candidates. Many of the genes up-regulated in
ovarian cancer
represent surface or secreted proteins such as claudin-3 and -4, HE4, mucin-1, epithelial cellular adhesion molecule, and
mesothelin
. Interestingly, both apolipoprotein E (ApoE) and ApoJ, two proteins involved in lipid homeostasis, are among the genes highly up-regulated in
ovarian cancer
. Selected serial analysis of gene expression results were further validated through immunohistochemical analysis of ApoJ, claudin-3, claudin-4, and epithelial cellular adhesion molecule in archival material. These experiments provided additional evidence of the relevance of our findings in vivo. The publicly available expression data reported here should stimulate and aid further research in the field of
ovarian cancer
.
...
PMID:Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. 1110 84
Several tumors, including mesothelioma and
ovarian cancer
, can overexpress
mesothelin
, a glycosylphosphatidylinositol-linked differentiation glycoprotein. The membrane-bound type of
mesothelin
is found in the blood of cancer patients at a very low level, which makes
mesothelin
a good candidate for targeted therapy of certain cancers. An antimesothelin disulfide-linked Fv (SS1 Fv) was fused to a truncated mutant of Pseudomonas exotoxin A to produce the recombinant immunotoxin SS1(dsFv)-PE38, which has a high binding affinity to
mesothelin
(Kd = 0.7 nM). Our studies in vitro showed that SS1(dsFv)-PE38 is significantly more cytotoxic to the high-
mesothelin
-producing NCI-H226 human non-small cell lung cancer cells than to human lung adenocarcinoma PC14PE6 cells, which do not express
mesothelin
. When administered at a nontoxic dose of 500 microg/kg on days 7, 9, and 11 to nude mice injected i.v. with the two human lung cancer cell lines, SS1(dsFv)-PE38 selectively inhibited experimental lung metastases produced by the
mesothelin
-producing NCI-H226 cells. Our data indicate that
mesothelin
-producing squamous cell carcinoma of the lung may be a good target for this immunotoxin.
...
PMID:Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. 1247 19
In an ongoing effort to design an efficacious, cost-effective
ovarian cancer
screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as
mesothelin
and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.
...
PMID:Ovarian cancer screening. 1295 88
We used DNA microarrays to characterize the global gene expression patterns in surface epithelial cancers of the ovary. We identified groups of genes that distinguished the clear cell subtype from other ovarian carcinomas, grade I and II from grade III serous papillary carcinomas, and ovarian from breast carcinomas. Six clear cell carcinomas were distinguished from 36 other ovarian carcinomas (predominantly serous papillary) based on their gene expression patterns. The differences may yield insights into the worse prognosis and therapeutic resistance associated with clear cell carcinomas. A comparison of the gene expression patterns in the ovarian cancers to published data of gene expression in breast cancers revealed a large number of differentially expressed genes. We identified a group of 62 genes that correctly classified all 125 breast and
ovarian cancer
specimens. Among the best discriminators more highly expressed in the ovarian carcinomas were PAX8 (paired box gene 8),
mesothelin
, and ephrin-B1 (EFNB1). Although estrogen receptor was expressed in both the ovarian and breast cancers, genes that are coregulated with the estrogen receptor in breast cancers, including GATA-3, LIV-1, and X-box binding protein 1, did not show a similar pattern of coexpression in the ovarian cancers.
...
PMID:Gene expression patterns in ovarian carcinomas. 1296 Apr 27
Mesothelin
is a glycosylphosphatidylinositol-linked cell surface molecule expressed in the mesothelial lining of the body cavities and in many tumor cells. Based on the finding that a soluble form of
mesothelin
specifically binds to ovarian carcinoma cell line OVCAR-3, we isolated cDNAs encoding a
mesothelin
-binding protein by expression cloning. The polypeptides encoded by the two cloned cDNA fragments matched to portions of CA125, an
ovarian cancer
antigen and a giant mucin-like glycoprotein present at the surface of tumor cells. By flow cytometric analysis and immunoprecipitation, we demonstrate that CA125 binds to
mesothelin
in a specific manner. Binding of CA125 to membrane-bound
mesothelin
mediates heterotypic cell adhesion as anti-
mesothelin
antibody blocks binding of OVCAR-3 cells expressing CA125 to an endothelial-like cell line expressing
mesothelin
. Finally, we show that CA125 and
mesothelin
are co-expressed in advanced grade ovarian adenocarcinoma. Taken together, our data indicate that
mesothelin
is a novel CA125-binding protein and that CA125 might contribute to the metastasis of
ovarian cancer
to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to
mesothelin
.
...
PMID:Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. 1467 94
Disruptions of the p53, retinoblastoma (Rb), and RAS signaling pathways and activation of human telomerase reverse transcriptase (hTERT) are common in human
ovarian cancer
; however, their precise role in
ovarian cancer
development is not clear. We thus introduced the catalytic subunit of hTERT, the SV40 early genomic region, and the oncogenic alleles of human HRAS or KRAS into human ovarian surface epithelial cells and examined the phenotype and gene expression profile of those cells. Disruption of p53 and Rb pathway by SV40 early genomic region and hTERT immortalized but did not transform the cells. Introduction of HRAS(V12) or KRAS(V12) into the immortalized cells, however, allowed them to form s.c. tumors after injection into immunocompromised mice. Peritoneal injection of the transformed cells produced undifferentiated carcinoma or malignant mixed Mullerian tumor and developed ascites; the tumor cells are focally positive for CA125 and
mesothelin
. Gene expression profile analysis of transformed cells revealed elevated expression of several cytokines, including interleukin (IL)-1beta, IL-6, and IL-8, that are up-regulated by the nuclear factor-kappaB pathway, which is known to contribute to the tumor growth of naturally
ovarian cancer
cells. Incubation with antibodies to IL-1beta or IL-8 led to apoptosis in the ras-transformed cells and
ovarian cancer
cells but not in immortalized cells that had not been transformed. Thus, the transformed human ovarian surface epithelial cells recapitulated many features of natural
ovarian cancer
including a subtype of
ovarian cancer
histology, formation of ascites, CA125 expression, and nuclear factor-kappaB-mediated cytokine activation. These cells provide a novel model system to study human
ovarian cancer
.
...
PMID:A genetically defined model for human ovarian cancer. 1499 24
Adenoviruses (Ads) are efficient gene transfer vehicles, but Ad-mediated gene therapy for
ovarian cancer
remains limited in vivo by inefficient and nonspecific gene transfer.
Mesothelin
(
MSLN
), a cell surface glycoprotein, is overexpressed in
ovarian cancer
but not in normal tissues except mesothelial cells. Therefore,
MSLN
is an attractive candidate for transcriptional and transductional targeting in the context of
ovarian cancer
gene therapy. We evaluated the expression of
MSLN
mRNA and
MSLN
surface protein in
ovarian cancer
cells. Ads containing the
MSLN
promoter driving reporter gene expression were created and tested in
ovarian cancer
cell lines and purified
ovarian cancer
cells isolated from patients. To evaluate transductional targeting, we used an Ad vector containing an Fc-binding domain within the fiber protein, which served as a docking domain for binding with anti-
MSLN
immunoglobulins. Both RT-PCR and flow cytometry revealed high
MSLN
gene and protein expression in
ovarian cancer
cells. The
MSLN
promoter was activated in
ovarian cancer
cells, but showed significantly reduced activity in normal control cells. Transductional targeting of Ads via anti-
MSLN
antibody increased transgene expression in
ovarian cancer
cells. This report describes the use of
MSLN
for transcriptional as well as transductional targeting strategies for
ovarian cancer
gene therapy.
...
PMID:Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. 1552 7
1
2
3
4
5
6
7
8
9
Next >>